IMNM
$20.71
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.
Intraday
Recent News
Did Reduced 2025 Losses and NDA Plans Just Shift Immunome's (IMNM) Investment Narrative?
Immunome, Inc. recently reported a lower full-year net loss for 2025, updated investors on progress in its oncology pipeline, and filed a US$156.03 million common stock shelf registration tied to an ESOP-related offering. A key angle for investors is how reduced losses alongside an expanded late-stage cancer portfolio and potential future equity issuance could shape Immunome’s financial and operational flexibility. Next, we will examine how Immunome’s reduced net loss and plans to file a New...
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing
Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing.
Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development
Immunome, Inc. (NASDAQ:IMNM) is one of the best cancer stocks to invest in now. On February 14, Immunome, Inc. (NASDAQ:IMNM) CEO and Chairman Clay Siegall reiterated heightened focus on building an oncology-focused pipeline centered on cell-surface-targeting agents and small molecules. The ultimate goal is to develop a targeted oncology platform for small molecules that can […]
Assessing Immunome (IMNM) Valuation After Recent Share Price Pullback
Immunome stock performance snapshot Immunome (IMNM) has drawn fresh attention after recent share price swings, with the stock up about 1.5% over the past day but showing a roughly 14% decline over the past month. See our latest analysis for Immunome. At the current share price of $22.12, Immunome’s recent 1 month share price return of about a 14% decline contrasts with a 90 day share price return of 18.7% and a very large 3 year total shareholder return. This suggests longer term momentum,...
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million
Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.